Aloe-Emodin

Aloe-Emodin

SCHEMBL972434

O=C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc21.c1ccc(CCc2ccccc2)cc1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.84
KMT2A Q03164 3/20 0.84
MAOA P21397 3/20 0.84
MAOB P27338 2/20 0.84
EPHX2 P34913 2/20 0.84
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
TSHR P16473 3/20 0.55
TDP1 Q9NUW8 3/20 0.55
LMNA P02545 2/20 0.55
HPGD P15428 2/20 0.55
ALOX15 P16050 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HSD17B10 Q99714 2/20 0.55
KDM4E B2RXH2 2/20 0.55
CYP3A4 P08684 2/20 0.55
RECQL P46063 2/20 0.55
TTR P02766 1/20 0.55
BCHE P06276 1/20 0.55
POLB P06746 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aloe-Emodin SCHEMBL8827767 0.92 MEN1 (0.94) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL309756 0.92 MEN1 (1.00) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL29398579 0.92 MEN1 (1.00) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL29814516 0.92 MEN1 (1.00) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL28079854 0.89 MEN1 (0.94) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL5857045 0.88 MEN1 (0.86) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL8929970 0.88 MEN1 (0.86) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL28756496 0.86 MEN1 (0.89) MEN1KMT2AMAOAMAOBEPHX2
Aloe-Emodin SCHEMBL1195370 0.84 MEN1 (0.80) MEN1KMT2AMAOAMAOBEPHX2
Rhein SCHEMBL5017539 0.84 MEN1 (0.80) MEN1KMT2AMAOAMAOBEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324411-B2 Process for the preparation of DIACEREIN LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) 2012-12-04 US disclosed
US-20110015269-A1 PROCESS FOR THE PREPARATION OF DIACERIN LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) 2011-01-20 US disclosed
EP-2234953-A1 PROCESS FOR THE PREPARATION OF DIACERIN Laboratorio Chimico Internazionale S.p.A. (IT) 2010-10-06 EP disclosed
WO-2009090483-A1 PROCESS FOR THE PREPARATION OF DIACERIN LABORATORIO CHIMICO INTERNAZIONALE S.P.A. (IT) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015269-A1 PROCESS FOR THE PREPARATION OF DIACERIN ALOX15B, ALOX12, ACAT1 MEN1 1265/4885KMT2A 3332/4885MAOA 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.